Lancet

• Latest
• Best
• Search…

• Lancet · Sep 2023

  Randomized Controlled Trial

  Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.

  In this study, we aimed to evaluate the efficacy, safety, and tolerability of atogepant for the preventive treatment of chronic migraine. ⋯ Allergan (now AbbVie).

  keep reading… mark as read…

• Lancet · Sep 2023

  Advancing integrated governance for health through national biodiversity strategies and action plans.

  no abstract available

  keep reading… or not…

• Lancet · Sep 2023

  What water will the UN Conference carry forward: a fundamental human right or a commodity?

  no abstract available

  read more… mark as read…

• Lancet · Sep 2023

  Comment

  Atogepant, the first oral preventive treatment for chronic migraine.

  no abstract available

  explore further… mark as read…

• Lancet · Sep 2023

  Regression of cutaneous xanthomata in patient with homozygous familial hypercholesterolemia using novel therapies.

  no abstract available

  read more… or not…